BioSpace News Archive

Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth.

STAAR Surgical Company reported financial results for the first quarter ended April 1, 2022.

CONMED Corporation announced financial results for the first quarter ended March 31, 2022.

Ligand Pharmaceuticals Incorporated reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates.

Repro Med Systems, Inc. dba KORU Medical Systems, a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, reported financial results for the first quarter ended March 31, 2022.

Acorda Therapeutics, Inc. will host a webcast/conference call in conjunction with its first quarter 2022 update and financial results on Wednesday, May 11 at 4:30 p.m. ET.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 23 newly-hired employees stock options to purchase an aggregate of 138,100 shares, and restricted stock units covering an aggregate of 69,050 shares, of BioCryst common stock.

Nephros, Inc. announced financial results for the first quarter ended March 31, 2022.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the first quarter ended March 31, 2022 and provided pipeline updates.

The U.S. Food and Drug Administration today permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease.